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We investigated the kinetic analysis of human platelet Nitric Oxide
Synthase (NOS) activity by the rate of conversion of [3H] arginine
to [3H]-citrulline in unstimulated fresh platelets. NOS activity was
present in the membrane fraction and cytosol, and was Ca2+- and
calmodulin dependent which is a characteristic of endothelial NOS.
NOS activity was also dependent of NADPH since the omission of
this cofactor induced an important decrease (85,2%) in the enzyme
activity. The kinetic varied with protein and arginine concentration
but optimum concentrations were found up to 60 minutes, and up
to 80 μg of protein at 120 nM of arginine and 0.5 μCi of 3H-arginine.
NOS activity in the absence of FAD (flavin adenine dinucleotide),
FMN (flavin mononucleotide) and BH4 (tetrahydrobiopterin) was
only 2.8% of the activity measured in the presence of these three
cofactors. The enzyme activity was completely inhibited by L-NAME
(1 mM) (98.1 %) and EGTA (5 mM) (98.8 %). Trifluoperazine (TFP)
caused 73.2% inhibition of the enzyme activity at 200 μM and
83.8 % at 500 μM. Under basal conditions, NOS Km for L-arginine
was 0.84 ± 0.08 μM and mean Vmax values were 0.122 ±
0.025 pmol.mg-1.min-1. Mean human NOS platelet activity was 0.020
± 0.010 pmol.mg-1.min-1. Results indicate that the eNOS in human
platelet can be evaluated by conversion of [3H]-arginine to [3H]-
citrulline in an optimized method, which provide reproducible and
accurate results with good sensitivity to clinical experiments
involving neurological and psychiatric diseases.
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INTRODUCTION
Platelets, skin fibroblasts, lymphocytes, plasma and
cerebrospinal fluid were identified in the search for
peripheral tissues or body fluids suitable for exploring
pathophysiology of neurodegenerative diseases such as
Alzheimer’s disease and psychiatric disorders, as
depression, bipolar disorder and panic disorder (Gasparini
et al., 1998). Platelets have been an important tool in
neuropsychiatry and in psychopharmacology research since
E. M. Kawamato, I. Glezer, C. D. Munhoz, C. Bernardes, C. Scavone, T. Marcourakis306
1955 (Pletscher, et al., 1956). A variety of biochemical
perspectives is offered by platelets since they can synthesize
a vast number of compounds, such as second messengers,
have metabolizing enzymes (MAO), express different kinds
of receptors, including adrenoceptors (α2 and β2), serotonin
(5-HT2) and benzodiazepine receptors (Pletscher, 1988,
Camacho, Dimsdale, 2000). Moreover, platelets share some
similarities with neurons mainly in respect to the uptake
system of serotonin (Pletscher, 1988). In addition, platelets
can be used as model for the study of stimulus-response
coupling mechanism since they yield homogeneous cell
suspension that respond reliably and quantifiably to many
pharmacological agonists (Hourani, Cusack, 1991).
The involvement of free radical in neuro-
degeneration is well established and the use of platelets to
assess the role of these agents is of great interest.
Peroxynitrite is formed from the interaction between nitric
oxide (NO) and superoxide anions. Interestingly, NO has
been suggested to protect against superoxide anion-
mediated injury under certain conditions (Miles et al.,
1996). NO is an important physiological messenger with
several biological functions such as regulation of vascular
tone, blood pressure, vasodilation, sodium excretion,
neurotransmission, macrophage cytotoxicity (Rees et al.,
1989; Aisaka et al., 1989; Garthwaite, Boulton, 1995;
Bredt, Snyder, 1990; Hibbs et al., 1990; Mckee et al.,
1994). Moreover, NO also inhibits platelet aggregation
through the activation of soluble guanylyl cyclase with the
production of cGMP (Radomski et al., 1990a; Radomski
et al., 1990b). NO synthase (NOS) is the enzyme
responsible for the oxidation of L-arginine to generate NO
and L-citrulline in a reaction that needs molecular oxygen,
NADPH as a co-substrate and BH4, FAD, FMN and Ca2+-
calmodulin as cofactors (Lincoln, Messersmith, 1995). In
humans, three distinct forms of NOS have been identified.
The neuronal NOS (nNOS) is found in neuronal and
epithelial cells and acts in neurotransmission. The
inducible NOS (iNOS) is found in macrophages and many
other cells (such as glia) after stimulation by inflammatory
signals such as cytokines or endotoxin. The endothelial
NOS (eNOS) is found basically in endothelial cells. The
activity of both eNOS and nNOS is Ca2+-calmodulin-
dependent, whereas that of iNOS is Ca2+-insensitive
(Bredt, Snyder, 1990; Mckee, et al., 1994).
Different methodological approaches have also
been used to characterize NOS isoforms in platelets. Thus,
studies using Western blots of cytosolic and membrane
fractions of human platelets as well as sequential affinity
chromatography were able to confirm the presence of a
Ca2+/CAM dependent isoform similar to the eNOS (Sase,
Michel, 1995; Muruganandam, Mutus, 1994). These
results are also supported by spectroscopic determination
(Radomski et al., 1990b), eletrochemical NO detection
(Lantoine et al., 1995) and porphyrinic microsensor assay
(Malinski et al., 1993), after platelet stimulation with
collagen. In addition, there is evidence for an inducible
isoform in human platelet NOS using reverse transcription
polymerase chain reaction (Mehta et al., 1995; Berkels et
al., 1997).
However, the problem among all these methods is
the lack of sensitivity because of the small amount of NO
production by platelets. Thus, the radiochemical assay
based on the biochemical conversion of L-arginine with
the production of stoechiometric quantities of L-citrulline
and NO is considered as a simple, sensitive and specific
method to measure the production of NO. When
optimized, the conversion assay can provide reproducible
and accurate results with good sensitivity.
We present here a method to the determination of
NOS activity in human platelets by the conversion of
tritium labeled L-arginine to tritium labeled L-citrulline.
NOS activity was assessed under a variety of different
conditions in order to optimize conditions for NOS activity
in platelet homogenate to permit using small volume of
whole blood and protein. Such information is important to
validate NOS studies in human and rat platelet as well as in
other peripheral tissues where eNOS has shown to act as an
intracellular messenger. Furthermore, the optimized study
will permit a simultaneous determination of the enzyme
activity, cyclic GMP levels and cyclic GMP-dependent
protein kinase activity in patients with several diseases.
MATERIALS AND METHODS
Chemicals
3H- Arginine (specific activity 45.2 Ci/mmol) was
obtained from Dupont – New England Nuclear (Natick,
MA) and scintillation cocktail was purchased from Ulti-
ma Gold TM (Packard BioScience BV, Groningen). 3H-
arginine from New England Nuclear is not 100% pure and
decomposition or bacterial contamination can bring
unspecific high radioactivity into the blank sample. Since
the levels of radioactivity in the blanks largely determine
the sensitivity of the assay, the 3H-arginine was purified
before NOS assay in human platelets. This was performed
by passing 3H-arginine through a Dowex ion-exchange
column. The column was washed four times with 1 mL of
distillated water, and the 3H-arginine was eluted with
0.02 M NaOH (2 mL). 3H-arginine was stored in aliquots
sufficient for each assay run to prevent contamination of
the stock. Dowex 50X8*-400, H+ form, ion exchange resin
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was supplied by Sigma-Aldrich Chemicals (St. Louis,
MO). The resin was converted to the sodium form by
washing in 1 N NaOH for approximately five minutes and
after in de-ionized water until pH 9-12, followed by
washing in HEPES buffer (pH=5,5) until pH < 7. HEPES,
sucrose, EDTA, dithiothreitol, PMSF, leupeptin, pepstatin,
calcium chloride, NADPH, calmodulin, FAD, FMN, BH4,
L-NAME and arginine were obtained from Sigma-Aldrich
Chemicals.
Preparation of washed platelets
The study was approved by the hospital’s ethic
committee and all subjects signed informed consent
forms. Blood from normal healthy volunteers (20 mL),
who were not taking any drug in the previous days, was
drawn from an antecubital vein into citrate acid dextrose
anticoagulant (2.73% citric acid, 3.68% sodium citrate,
2% glucose). Platelet rich plasma was prepared within 30
min after blood collection by centrifuging the blood at 394
x g. The plasma was then centrifuged at 1500 x g to obtain
the platelet pellet. The pellet was washed twice in Krebs
buffer (pH 6) containing [mM] 140 NaCl, 5 KCl, 12
sodium citrate, 10 glucose, 12.5 sucrose and centrifuged
at 1500 x g. All centrifugations were performed for 15 min
at room temperature.
The platelets were ressuspended in a buffer (pH 7.4)
with 20 mM HEPES, 0.32 mM sucrose, 1 mM dithio-
threitol (DTT), 10 μg/mL leupeptin, 0.1 mM EDTA,
1 mM pepstatin, 1 mM PMFS, and sonicated at 4 °C. The
sample was then treated with the ion-exchange resin
(Dowex 50WX8-400, sodium form) to remove endo-
genous arginine. NOS activity was measured in the
homogenate with an assay adapted from methods
published previously (Bredt, Snyder, 1990; Mckee et al.,
1994).
Determination of Nitric Oxide Synthase Activity
(NOS) in platelets
The incubation medium (pH=7.4) contained 4 μM
FAD, 4 μM FMN, 10 μg/mL calmodulin, 1.25 mM Ca2+,
1 mM NADPH, 25 μM BH4 and one of the three different
L-arginine concentrations (10 μM, 1 μM, 120 nM). The
reaction was started by adding the platelet samples in the
desired protein concentration. Total platelet protein was
determined in the homogenate using Biorad (Melville,
NY) assay (Bradford, 1976).
After 30 and 60 minutes of incubation at 37 °C, the
reaction was stopped by the addition of 1 mL of cold
Hepes 20 mM (pH=5.5) and keeping the tubes in ice. 3H-
citrulline was separated from 3H-arginine through an ion
exchange resin column (Dowex 50WX8-400, sodium
form) and the addition of 1 mL of distilled water. Total
eluate was collected in a scintillation vial containing 10 mL
of Ultima Gold scintillation fluid. The radioactivity was
determined in a Packard Liquid Scintillation Counter with
54% efficiency. Blanks consisted of homogenizing
medium, without platelet samples, which was carried out
through the identical process. All measurements were
made in triplicate and corrected for the appropriate blanks.
Total count refers to a vial containing [3H]-arginine and L-
arginine without passing by the resin. The data were
converted from cpm to dpm and specific activity
(pmol.mg-1.min-1) was calculated by using the following
formula: [arginine] x [sample count]/[total count] x [protein]
x time. Determination of Km and Vmax was done based
on Lineweaver-Burk regression (Conrad, Davis, 1995).
RESULTS
Linearity with time, protein and substrate
concentration
It might be assumed that NOS assay is highly
dependent on the enzyme concentration and the
incubation time. However, the activity of the enzyme can
rapidly reach a plateau with time and with protein
concentration. Thus, the first step was to determine the
optimum conditions of time incubation and protein
concentration to ensure that this plateau has not been reach
as suggested by Hevel and Marletta (1994). For kinetic
analysis of platelet NOS activity, it was necessary to carry
out the NOS assay using different concentrations of the L-
arginine substrate. Therefore, three different L-arginine
concentrations were tested: 10 μM, 1 μM, 120 nM with a
fixed concentration of 3H-arginine (0.5 μCi) (Figure 1).
The increase of 3H-arginine concentration was not useful
as NOS activity did not increase with higher concen-
trations of that (data not shown). Preliminary experiments
demonstrated that under standard conditions the assay was
linear when protein concentration was up to 80 μg and the
time of reaction was up to 60 minutes at 120 nM of
arginine (Figure 1). Under basal conditions, NOS Km for
L-arginine was 0.84 ± 0.08 mM and mean Vmax values
were 0.122 ± 0.025 pmol.mg-1.min-1. Mean human NOS
platelet activity was 0.020 ± 0.010 pmol.mg-1.min-1.
Cofactor requirement of platelet NOS activity
Figure 2 shows the dependence of cofactor on
platelet NOS activity. Almost no platelet NOS activity
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Inhibition of human NOS platelet by L-NAME
L-NAME (10 μM and 1 mM), a inhibitor of the all
isoforms of NOS was used to characterize the enzyme. L-
NAME (10 μM) inhibited approximately 70% of platelet
NOS and 1 mM caused a complete inhibition of this
enzyme activity (Figure 3). The total NOS activity can be
expressed as the difference in activity in the presence and
absence of L-NAME.
FIGURE 2 - Effects of the co-factors, FAD, BH4 and FMN, on NOS activity in human platelet. The clear bar represents
control activity under standard conditions. Cofactors were investigated either singly (single hatching) or in combination
(cross hatching). The concentration (M) used has been indicated under each bar. The composition of all the other
components of the incubating medium was kept constant. Results were expressed as pmol. mg-1. min-1 and have been
given as the mean ± SEM of 3-5 experiments each consisting of triplicate determination.
FIGURE 1 - Effect of arginine, protein concentration, and incubation time on NOS activity in a preparation from fresh
human platelet. Three different L-arginine concentrations (10 μM, 1 μM, 120 nM) were tested with different protein
concentration (40 ?, 80 ? and 160 ug ?) a fixed concentration of 3H-arginine (0.5 μCi) at 30 and 60 minutes of
incubation. Results have been expressed as cpm, which was corrected for its own blank (homogenate omitted). Data
consist of a representative experiment, which was repeated, and have been given as the mean of triplicate determination.
(approximately 2.8%) was detected when none of the
cofactors were added to the incubation medium. The
addition of FAD, FMN or BH4 individually, enhances
platelet NOS activity, but not to the level observed when
they were present all together. The combination of two of
the cofactors (FAD+FMN, FAD+BH4, FMN+BH4)
produced an increase on activity, but neither was able to
reach the maximum enzyme activity. Therefore, the
optimum activity was achieved using only all three (4 μM
FAD, 4 μM FMN, 25 μM BH4) cofactors.
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Ca
2+
/calmodulin
 
dependence on platelet NOS activity
To further characterize human NOS platelet activity,
it is important to test Ca2+-calmodulin dependence of this
enzyme. To this purpose, a range of Ca2+ concentration
was added to the incubation medium: 0, 0.625, 1.25
(reference concentration) (Figure 4). In addition, EGTA
was used as a calcium chelator (1 mM and 5 mM) and two
different concentration (200 and 500 mM) of TFP were
used to determine calmodulin dependence in NOS platelet
(Figure 3)
EGTA caused 80% inhibition of NOS activity at
1 mM and total inhibition at 5mM (Figure 5). The
optimum concentration of NADPH was 1.0 mM and of
FIGURE 3 - Effects of the co-substrate, NADPH, and of the inhibitors, L-NAME , EGTA and TFP, on NOS activity in
human platelet. The clear bar represents control activity measured under standard conditions. The incubation media were
altered as indicated under each of the hatched bars. Results are expressed as pmol. mg-1. min-1 and have been given as
the mean ± SEM of 3-5 experiments each consisting of triplicate determination.
FIGURE 4 - Effects of Ca2+ concentration on NOS activity in human platelet. The clear bar represents control activity
measured under standard conditions (Ca2+ concentration, 1.25 mM). Ca2+ concentrations were altered as indicated under
the hatched bars. Note that these concentrations represent those added exogenously and not the final concentration in
the incubation medium which contains a non-specific chelator, EDTA. Results are expressed as pmol. mg-1. min-1 and
have been given as the mean ± SEM of 3-5 experiments each consisting of triplicate determination.
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Ca2+ was 1.25 mM (Figure 3). Increases of NADPH
concentration and Ca2+ induced a reduction of 140% and
60 % of the NOS activity, respectively (Figure 3). TFP
induced 73.2% inhibition of the enzyme activity at
200 mM and 83.8 % at 500 mM (Figure. 3)
DISCUSSION
In the present study, an optimized NOS assay was
characterized from a preparation of homogenate of human
platelet. Preliminary results suggest that although eNOS
activity in platelets is membrane-bound and is thus
localized in the particulate fraction, we could detect NOS
enzyme activity in platelet cytosol, as well as in
homogenate of human platelets disrupted by sonication.
The profile of higher NOS activity in human platelet
homogenate when compared to either membrane or
cytosol correlates well with results reported by Sase and
Michel (1995), and suggests that this fraction should be
used for studying the basic biochemical features of eNOS
in platelet.
Evidences emerging from various laboratories
shows that there are several different conditions in the
assay of NOS activity in platelet, like different time of
incubation, different concentrations of cofactors,
NADPH, buffer, protein, L-arginine, [3H]-arginine (Chen,
Mehta, 1996; Mehta et al., 1995; Riddell et al., 1997;
Sase, Michel, 1995). In addition, it has been reported that
only large amount of whole blood (from ~ 200 mL of
whole blood) and protein (~ 10 mg/mL) has to be used in
order to obtain a good NOS activity in human platelet
(Sase, Michel, 1995). However, the kinetic analysis of
NOS activity by using different concentrations of the L-
arginine, and other requirements for eNOS activity has not
been evaluated in human NOS platelet study. It is very
important to establish that the concentration of arginine
used is not rate limiting since it might be hard to
demonstrate changes in the enzyme activity in experimen-
tal study where NOS activity increases (Lincoln,
Messersmith, 1995). Our results confirm previous
findings that the sensitivity of NOS assay on platelets is
very low when compared with NOS activity on
cerebellum (Sase, Michel, 1995; Mckee et al., 1994).
Since the basis of the NOS assay is to measure the
conversion of radioactive arginine to citrulline, the higher
the levels of endogenous, non-radioactive arginine, the
lower is the sensitivity of the assay. Therefore, it was
necessary to remove endogenous arginine from crude
supernatants by passing the sample through a Dowex ion-
exchange column. In addition, it was important to run
control experiments in which NOS activity was measured
after different incubation times and using different
concentrations of tissue. Our experiments showed that the
linear portion of the curve could be obtained with 80 µg of
protein at 30 and 60 minutes of incubation.
The kinetic analysis of platelet NOS activity was
based on Garvey et al. (1994) and Wolf et al. (1994) by
using three different L-arginine concentrations with a
fixed concentration of 3H-arginine (0.5 μCi). In order to
have high enough arginine concentration in the assay, 3H-
arginine can be mixed with non-radioactive arginine.
Thus, it was necessary to determine the relative
proportions of radioactive and non-radioactive arginine in
the working solution so that the change in specific activity
of 3H-arginine can be calculated. Experiments in platelets
using 1 and 10 mM concentration of L-arginine have
obtained high NOS activity but there is a reduction in
specific activity, which reduce the sensitivity of the assay.
In addition, the dose-response curve was not linear when
high concentrations of arginine were used in NOS assay.
Thus, the working solution with the best specific activity
was obtained in the presence of 120 nM of L-arginine with
a fixed concentration of 3H-arginine (0.5 μCi). Under
basal conditions, NOS Km for L-arginine was 0.84 ±
0.08 μM and mean Vmax values were 0.122 ±
0.025 pmol.mg-1.min-1. Mean human NOS platelet activity
was 0.020 ± 0.010 pmol.mg-1.min-1 .
The dependence of the presence of co-substrate and
cofactors in NOS activity have been reported in different
tissue preparation, such as kidney, myenteric plexus,
dorsal brain stem, neutrophils, dorsal periaquedutal gray,
spinal cord and LLC-PK1 cells (Lincoln, Messersmith,
1995; Mckee et al., 1994; Barjavel, Bhargava, 1995;
Pontieri et al., 1998; Cerchiaro et al., 2001; Chiavegatto
et al., 1998). Our results also demonstrated a dependence
of the presence of co-factor when measuring NOS activity
in platelet homogenate. However, previous studies have
reported that FMN concentrations had little effect when
compared to FAD and BH4 in NOS activity in crude
cytosolic preparation (Lincoln, Messersmith, 1995). The
present data showed that in platelet, all three co-factors
had to be added for maximal activity to occur, and the
absence of any of them induced an important decrease in
NOS activity. In fact, NOS activity in the absence of FAD,
FMN and BH4 was only 2.8% of the activity measured in
the presence of these three cofactors. The intracellular
concentration of FAD (4 μM) and FMN (4 μM) required
to maximal activity in platelet was similar to that reported
to other tissues (Mckee et al., 1994, Sase, Michel, 1995).
However, the intracellular concentration of BH4 under
normal physiological conditions in platelet is not
established. Thus, we used a range of intracellular
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concentration of BH4 from 0.25 to 25 µM and the maximal
activity was achieved with 25 µM.
 The enzyme activity was completely inhibited by
L-NAME (1 mM) (98.1 %) and EGTA (5 mM) (98.8 %).
The results also showed that human platelet NOS activity
is highly dependent on NADPH and Ca2+ in the incubation
medium since the absence of both induced a tremendous
decrease in the enzyme activity. Interestingly, the increase
of Ca2+ concentration above 1.25 mM resulted in
inhibition of NOS activity. It should be noted that Ca2+
concentration added in the medium does not represent the
final free Ca2+ concentration since the non-specific
divalent cation chelator EDTA is present in the homo-
genizing buffer. It should be noted that the omission of
calmodulin from the incubating media was not sufficient
to induce any decrease in the enzyme activity (data not
shown) probably due to the binding of this compound to
the enzyme during tissue preparation as it has been
suggested to iNOS (Cho et al., 1992). However, TFP, a
calmodulin antagonist, caused 73.2% inhibition of the
enzyme activity at 200 µM and 83.8 % at 500 μM.
Therefore, the present studies indicate that NOS
activity in human platelet are highly dependent on the
appropriate substrate and Ca2+ concentration, as well as on
exogenous co-fators for maximal activity. Given the
extensive involvement of NOS in disease states, the
procedure described here should be able to provide good
indications of NOS activity in human platelet when
investigating changes in the enzyme activity in patho-
logical conditions.
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RESUMO
Atividade da Óxido Nítrico Sintase em plaquetas hu-
manas: um método otimizado
A análise cinética da atividade da óxido nítrico sintase
(NOS) plaquetária foi avaliada pela conversão de
[3H]-arginina em [3H]-citrulina em plaquetas humanas
frescas não estimuladas. A atividade da NOS foi detecta-
da na fração citosólica e na membrana, além de ser de-
pendente de Ca2+-calmodulina, que é uma característica
da NOS endotelial (eNOS). A omissão de NADPH levou
à diminuição da atividade da NOS dependente da dose
causando redução de 85,2% da atividade enzimática. A
cinética variou de acordo com as concentrações de pro-
teína e de arginina, sendo que as melhores leituras foram
obtidas com 80 μg de proteína, 120 nM de arginina em
0,5 μCi  de 3H arginina, em 60 minutos de incubação. A
atividade da NOS na ausência de FAD (flavina adenina
dinucleotídeo), FMN (flavina mononucleotídeo) e BH4
(tetrahidrobiopterina) foi de apenas 2,8% da atividade
medida na presença destes três cofatores. A atividade da
enzima foi completamente inibida pelo L-NAME (1 mM;
98,1 %), EGTA (5 mM; 98,8 %) e adição de trifluo-
perazina (TFP), nas concentrações de 200 μM e 500 μM,
inibiu a atividade da enzima em 73,2% e 83,8 %, respec-
tivamente. Em condições basais, o Km da NOS para L-
arginina foi de 0,84 ± 0,08 μM e o valor de Vmax foi de
0,122 ± 0,025 pmol.mg-1.min-1. A atividade média da NOS
plaquetária humana foi de 0,020 ± 0,010  pmol.mg-1.min-1.
Os resultados indicam que a eNOS em plaquetas humanas
pode ser avaliada pelo método da conversão de
[3H]-arginina em [3H]-citrulina, que em condições
otimizadas, fornece resultados reprodutíveis e precisos
com ótima sensibilidade para experimentos clínicos en-
volvendo doenças neurológicas e psiquiátricas.
UNITERMOS: NOS. Plaquetas. Humano. Arginina.
Citrulina.
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